➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Boehringer Ingelheim
Merck

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Patent: 8,647,842

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,647,842
Title:Methods for producing a fusion protein capable of binding VEGF
Abstract: The present invention provides methods for producing a fusion protein capable of binding vascular endothelial cell growth factor (VEGF). The methods of the invention comprise growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule encoding a fusion protein that binds VEGF, and isolating the fusion protein from the suspension culture. The fusion protein may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
Inventor(s): Papadopoulos; Nicholas J. (Lagrangeville, NY), Davis; Samuel (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:13/439,889
Patent Claims:see list of patent claims

Details for Patent 8,647,842

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2019-06-08 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
Harvard Business School
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.